{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:19:47Z","timestamp":1790623187551,"version":"4.1.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T00:00:00Z","timestamp":1481241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["114024032"],"award-info":[{"award-number":["114024032"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0167195","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T19:59:00Z","timestamp":1481313540000},"page":"e0167195","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":42,"title":["Inhibition of Interleukin-6 Receptor in a Murine Model of Myocardial Ischemia-Reperfusion"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6965-3259","authenticated-orcid":true,"given":"Minke H. T.","family":"Hartman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Vreeswijk-Baudoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde E.","family":"Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kees W. A.","family":"van de Kolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Mateo Leach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozemarijn","family":"Vliegenthart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman H. W.","family":"Sillje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim","family":"van der Harst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,12,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrcardio.2011.154","article-title":"Cardiac remodeling at the population level\u2014risk factors, screening, and outcomes","volume":"8","author":"O Gjesdal","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10741-010-9181-7","article-title":"Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities","volume":"16","author":"JJ Gajarsa","year":"2011","journal-title":"Heart Fail Rev"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcmg.2010.10.008","article-title":"Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment","volume":"4","author":"MA Konstam","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"974694","DOI":"10.1155\/2010\/723589","article-title":"Pro\/Anti-inflammatory cytokine imbalance in postischemic left ventricular remodeling","volume":"2010","author":"AL Pasqui","year":"2010","journal-title":"Mediators Inflamm"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"PG Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1096\/fj.99-1003rev","article-title":"The soluble interleukin 6 receptor: mechanisms of production and implications in disease","volume":"15","author":"SA Jones","year":"2001","journal-title":"FASEB J"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cellsig.2012.12.008","article-title":"p42\/p44-MAPK and PI3K are sufficient for IL-6 family cytokines\/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK\/STAT activation","volume":"25","author":"A Fahmi","year":"2013","journal-title":"Cell Signal"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cardiores.2005.08.017","article-title":"IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes","volume":"69","author":"N Smart","year":"2006","journal-title":"Cardiovasc Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"38829","DOI":"10.1074\/jbc.M210584200","article-title":"Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE)","volume":"278","author":"V Matthews","year":"2003","journal-title":"J Biol Chem"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","article-title":"Interleukin-6 and its receptors: a highly regulated and dynamic system","volume":"70","author":"J Wolf","year":"2014","journal-title":"Cytokine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.cyto.2013.03.020","article-title":"IL-6 and its receptors in coronary artery disease and acute myocardial infarction","volume":"62","author":"DR Anderson","year":"2013","journal-title":"Cytokine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10753-011-9326-4","article-title":"Subacute inflammatory activation in subjects with acute coronary syndrome and left ventricular dysfunction","volume":"35","author":"L De Gennaro","year":"2012","journal-title":"Inflammation"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.atherosclerosis.2009.03.033","article-title":"Coronary sinus concentrations of interleukin 6 and its soluble receptors are affected by reperfusion and may portend complications in patients with myocardial infarction","volume":"206","author":"KA Kaminski","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"N Sarwar","year":"2012","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis","volume":"379","author":"AD Hingorani","year":"2012","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0165-2478(02)00202-X","article-title":"Characterization of anti-mouse interleukin-6 receptor antibody","volume":"84","author":"M Okazaki","year":"2002","journal-title":"Immunol Lett"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1006\/cyto.2002.2012","article-title":"Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice","volume":"20","author":"A Katsume","year":"2002","journal-title":"Cytokine"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1148\/radiol.2353040601","article-title":"Effect of endocardial trabeculae on left ventricular measurements and measurement reproducibility at cardiovascular MR imaging","volume":"236","author":"T Papavassiliu","year":"2005","journal-title":"Radiology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jsbmb.2012.06.004","article-title":"The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload","volume":"132","author":"LM Meems","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","article-title":"Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis","volume":"6","author":"L Yu","year":"2013","journal-title":"Circ Heart Fail"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.intimp.2008.07.002","article-title":"Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production","volume":"8","author":"Y Uchiyama","year":"2008","journal-title":"Int Immunopharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0165-2478(02)00201-8","article-title":"Influences of anti-mouse interleukin-6 receptor antibody on immune responses in mice","volume":"84","author":"M Mihara","year":"2002","journal-title":"Immunol Lett"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"N Nishimoto","year":"2008","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/cvr\/cvq078","article-title":"Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice","volume":"87","author":"M Kobara","year":"2010","journal-title":"Cardiovasc Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1161\/CIRCULATIONAHA.109.916346","article-title":"Monocytes: protagonists of infarct inflammation and repair after myocardial infarction","volume":"121","author":"M Nahrendorf","year":"2010","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/ATVBAHA.110.218685","article-title":"Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction","volume":"31","author":"AC Sposito","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","article-title":"The IL-6\/gp130\/STAT3 signaling axis: recent advances towards specific inhibition","volume":"34C","author":"C Garbers","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/ATVBAHA.111.229435","article-title":"Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice","volume":"32","author":"H Schuett","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/CIRCHEARTFAILURE.112.972653","article-title":"Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)","volume":"6","author":"ET Askevold","year":"2013","journal-title":"Circ Heart Fail"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s11897-014-0185-9","article-title":"Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure","volume":"11","author":"ET Askevold","year":"2014","journal-title":"Curr Heart Fail Rep"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/labinvest.3700322","article-title":"Interleukin-6\/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis","volume":"85","author":"K Matsushita","year":"2005","journal-title":"Lab Invest"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/keu168","article-title":"The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis","volume":"53","author":"AP Malaviya","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"O Kleveland","year":"2016","journal-title":"Eur Heart J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0167195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T13:39:34Z","timestamp":1589031574000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0167195"}},"subtitle":[],"editor":[{"given":"Germ\u00e1n E.","family":"Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,12,9]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0167195","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,9]]}}}